A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40
mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.